An­gion, still reel­ing from past de­feats, scraps a PhII kid­ney dis­ease study af­ter 'un­ex­pect­ed' safe­ty event

Faced with a litany of set­backs over its lead pro­gram last year, An­gion Bio­med­ica is now re­port­ing a new ob­sta­cle in a fol­low-up can­di­date.

An­gion is dis­con­tin­u­ing a Phase II tri­al eval­u­at­ing oral TKI in­hibitor ANG-3070, the com­pa­ny said Wednes­day af­ter­noon, af­ter an un­ex­pect­ed safe­ty is­sue popped up in the study’s treat­ment arm. Re­searchers had been en­rolling pa­tients with se­ri­ous kid­ney dis­eases, in­clud­ing fo­cal seg­men­tal glomeru­loscle­ro­sis (FS­GS) and im­munoglob­u­lin A nephropa­thy (IgAN).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER